checkAd
    Startseite > Aktien > Natera > Nachrichten
    Natera Aktie
    90,42
     
    USD
    -4,29 %
    -4,05 USD
    Letzter Kurs 02:00:00 Nasdaq
    90,38
     
    USD
    600 STK
    Geldkurs 15.04.24
    90,42
     
    USD
    400 STK
    Briefkurs 15.04.24
    ISIN: US6323071042 · WKN: A14VPJ · SYM: NTRA · USA

    Neueste Nachrichten

    Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
    11.04.24 · Business Wire (engl.) · Natera
    Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients
    08.04.24 · Business Wire (engl.) · Natera
    Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
    05.04.24 · Business Wire (engl.) · Natera
    Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
    01.04.24 · Business Wire (engl.) · Natera
    Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera in Stage II Colorectal Cancer
    18.03.24 · Business Wire (engl.) · Natera
    New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
    14.03.24 · Business Wire (engl.) · Natera
    Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
    12.03.24 · Business Wire (engl.) · Natera
    Natera Announces Commercial Coverage for Prospera Kidney and Prospera Heart from a Top BCBS Plan
    07.03.24 · Business Wire (engl.) · Natera
    Natera to Participate in March Investor Conferences
    29.02.24 · Business Wire (engl.) · Natera
    Natera Reports Fourth Quarter and Full Year 2023 Financial Results
    28.02.24 · Business Wire (engl.) · Natera
    Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
    27.02.24 · Business Wire (engl.) · Natera
    Medicare Extends Coverage of Natera’s Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
    26.02.24 · Business Wire (engl.) · Natera